New injection aims to calm overactive immune cells in arthritis patients
NCT ID NCT07349420
First seen Jan 16, 2026 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This early-stage study tested a new drug called EF-M2 in 48 adults with moderate-to-severe rheumatoid arthritis. The treatment is designed to reprogram immune cells to reduce inflammation. The main goal was to check safety and side effects, while also looking at how the drug affects the body's immune response and arthritis symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for New Medical Technologies
Novosibirsk, Novosibirsk Oblast, 630090, Russia
Conditions
Explore the condition pages connected to this study.